European heart journal. Case reports · 2026
Isolated posterior mitral leaflet elongation as a rare mechanism of systolic anterior motion in hypertrophic cardiomyopathy: a case report of successful treatment with mavacamten.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gomez Luis Enrique, Buonfiglio Paula Inés, Ackerman Judith, Bruque Carlos David, Atamañuk Andres Nicolas
Аннотация
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder. Left ventricular outflow tract (LVOT) obstruction typically results from systolic anterior motion (SAM) of the anterior mitral leaflet.
CASE SUMMARY: We describe a 26-year-old man with HCM in whom SAM was generated by isolated elongation of the posterior mitral leaflet, a rare mechanism with important clinical implications. He was diagnosed during childhood by a paediatric cardiologist and followed until transition to adult care. On presentation, he was in NYHA (New York Heart Association) class II with asymmetric septal hypertrophy (25 mm) and posterior leaflet elongation causing LVOT obstruction. Cardiac magnetic resonance confirmed hypertrophy and late gadolinium enhancement at the site of maximal wall thickness. Genetic testing revealed a pathogenic MYH7 variant (p.Ile263Thr) and a MYH6 classified as of uncertain significance. Treatment with mavacamten 5 mg led to a reduction of the LVOT gradient from 63 to 32 mmHg and symptomatic improvement.
DISCUSSION: This case illustrates an unusual anatomical substrate for LVOT obstruction in HCM and emphasizes the role of multimodality imaging in diagnosis. It also highlights the therapeutic potential of myosin inhibition with mavacamten in avoiding invasive interventions in complex phenotypes.
CASE SUMMARY: We describe a 26-year-old man with HCM in whom SAM was generated by isolated elongation of the posterior mitral leaflet, a rare mechanism with important clinical implications. He was diagnosed during childhood by a paediatric cardiologist and followed until transition to adult care. On presentation, he was in NYHA (New York Heart Association) class II with asymmetric septal hypertrophy (25 mm) and posterior leaflet elongation causing LVOT obstruction. Cardiac magnetic resonance confirmed hypertrophy and late gadolinium enhancement at the site of maximal wall thickness. Genetic testing revealed a pathogenic MYH7 variant (p.Ile263Thr) and a MYH6 classified as of uncertain significance. Treatment with mavacamten 5 mg led to a reduction of the LVOT gradient from 63 to 32 mmHg and symptomatic improvement.
DISCUSSION: This case illustrates an unusual anatomical substrate for LVOT obstruction in HCM and emphasizes the role of multimodality imaging in diagnosis. It also highlights the therapeutic potential of myosin inhibition with mavacamten in avoiding invasive interventions in complex phenotypes.